无输血依赖时间（TWiTR）：基于3期SIMPLIFY - 1、SIMPLIFY - 2和MOMENTUM试验，将生存质量纳入骨髓纤维化治疗策略
Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials.
作者信息
Mesa Ruben A, Talpaz Moshe, Mazerolle Flora, Gorsh Boris, M'Hari Manal, Regnault Antoine, Ellis Catherine, Wang Zhaohui, Purser Molly, Liu Tom, Strouse Bryan, Patnaik Dwaipayan
机构信息
Atrium Health Wake Forest Baptist Comprehensive Cancer Center Winston-Salem North Carolina USA.
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan USA.
出版信息
EJHaem. 2025 Jun 18;6(3):e70075. doi: 10.1002/jha2.70075. eCollection 2025 Jun.
INTRODUCTION
Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with poorer survival and quality of life.
METHODS
Time without transfusion reliance (TWiTR), a method integrating transfusion dependence and survival quality, was applied to three Phase 3 trials of momelotinib in myelofibrosis.
RESULTS
TWiTR demonstrated that patients treated with momelotinib versus comparators spent more time free from transfusions and anemia events.
CONCLUSION
Momelotinib may lead to improved survival quality for patients with myelofibrosis.
TRIAL REGISTRATION
ClinicalTrials.gov identifiers: NCT01969838, NCT02101268, and NCT04173494.
简介
骨髓纤维化的特征是出现使人虚弱的全身症状和贫血，这对生存率和生活质量产生负面影响。红细胞输血是骨髓纤维化贫血治疗的基础，但对输血的依赖进一步与较差的生存率和生活质量相关。
方法
无输血依赖时间（TWiTR）是一种综合输血依赖和生存质量的方法，应用于三项momelotinib治疗骨髓纤维化的3期试验。
结果
TWiTR表明，与对照药物相比，接受momelotinib治疗的患者无输血和贫血事件的时间更长。
结论
Momelotinib可能会改善骨髓纤维化患者的生存质量。
试验注册
ClinicalTrials.gov标识符：NCT01969838、NCT02101268和NCT04173494。
Zotero 插件